Experienced in Thymic Epithelial Tumor

Reyes Bernabe

Sevilla, AN, ES 
Clinical Trials:Currently Recruiting for 1 Trial
Experienced in Thymic Epithelial Tumor
Sevilla, AN, ES 
OverviewLocationsClinical Research

Overview

Reyes Bernabe practices in Sevilla, Spain. Bernabe is rated as an Experienced expert by MediFind in the treatment of Thymic Epithelial Tumor. Their top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), EGFR Positive Lung Cancer, and Tissue Biopsy.

Their clinical research consists of co-authoring 48 peer reviewed articles and participating in 15 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 3 articles and participated in 1 clinical trial in the study of Thymic Epithelial Tumor.

Locations

Sevilla, AN, Spain
Other Locations
Barcelona, CT, Spain
Hospital Universitari Dr. Josep Trueta, Las Palmas De Gran Canaria And Hospital Universitario Dr. Balmis Alicante, Alicante, VC, Spain

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

15 Clinical Trials

Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects With Non-Small Cell Lung Cancer With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects With Non-Small Cell Lung Cancer With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
Enrollment Status: Recruiting
Publish Date: June 27, 2025
Intervention Type: Drug
Study Drug: APL-101
Study Phase: Phase 2
A Multicentric, Open-Label, Single Arm Phase II Study To Evaluate The Efficacy And Safety Of The Combination Of PEmbrolizumab And Lenvatinib In Pre-Treated Thymic Carcinoma PaTIents. PECATI.
A Multicentric, Open-Label, Single Arm Phase II Study To Evaluate The Efficacy And Safety Of The Combination Of PEmbrolizumab And Lenvatinib In Pre-Treated Thymic Carcinoma PaTIents. PECATI.
Enrollment Status: Active_not_recruiting
Publish Date: July 02, 2025
Intervention Type: Drug
Study Drugs: Pembrolizumab, Lenvatinib
Study Phase: Phase 2
A Multicentre Randomised Phase III Trial Comparing Atezolizumab Plus Bevacizumab and Standard Chemotherapy Versus Bevacizumab and Standard Chemotherapy as First-line Treatment for Advanced Malignant Pleural Mesothelioma
A Multicentre Randomised Phase III Trial Comparing Atezolizumab Plus Bevacizumab and Standard Chemotherapy Versus Bevacizumab and Standard Chemotherapy as First-line Treatment for Advanced Malignant Pleural Mesothelioma
Enrollment Status: Completed
Publish Date: June 04, 2025
Intervention Type: Drug
Study Drugs: Carboplatin, Pemetrexed, Bevacizumab, Atezolizumab
Study Phase: Phase 3
A Phase III Clinical Trial of Adjuvant Chemotherapy vs Chemoimmunotherapy for Stage IB-IIIA Completely Resected Non-small Cell Lung Cancer (NSCLC) Patients.
A Phase III Clinical Trial of Adjuvant Chemotherapy vs Chemoimmunotherapy for Stage IB-IIIA Completely Resected Non-small Cell Lung Cancer (NSCLC) Patients.
Enrollment Status: Active_not_recruiting
Publish Date: April 10, 2025
Intervention Type: Drug
Study Drugs: Carboplatin, Paclitaxel, Nivolumab
Study Phase: Phase 3
A Randomized Phase II Study of Neo-adjuvant Chemo/Immunotherapy Versus Chemotherapy Alone for the Treatment of Locally Advanced and Potentially Resectable Non-small Cell Lung Cancer (NSCLC) Patients.
A Randomized Phase II Study of Neo-adjuvant Chemo/Immunotherapy Versus Chemotherapy Alone for the Treatment of Locally Advanced and Potentially Resectable Non-small Cell Lung Cancer (NSCLC) Patients.
Enrollment Status: Active_not_recruiting
Publish Date: April 09, 2025
Intervention Type: Drug
Study Drugs: Paclitaxel, Carboplatin, Nivolumab
Study Phase: Phase 2
A Phase II Trial of Neoadjuvant Treatment Carboplatin-Pemetrexed-Bevacizumab Plus Atezolizumab for the Treatment of Locally Advanced and Potentially Resectable NSCLC Patients With EGFR Mutations
A Phase II Trial of Neoadjuvant Treatment Carboplatin-Pemetrexed-Bevacizumab Plus Atezolizumab for the Treatment of Locally Advanced and Potentially Resectable NSCLC Patients With EGFR Mutations
Enrollment Status: Terminated
Publish Date: April 02, 2025
Intervention Type: Drug
Study Drugs: Atezolizumab, Bevacizumab, Carboplatin, Pemetrexed
Study Phase: Phase 2
A Screening Protocol to Determine Tumor Antigen Expression and HLA Sub-Type for Eligibility Determination for Clinical Trials Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs in Subjects With Solid and Hematological Malignancies
A Screening Protocol to Determine Tumor Antigen Expression and HLA Sub-Type for Eligibility Determination for Clinical Trials Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs in Subjects With Solid and Hematological Malignancies
Enrollment Status: Completed
Publish Date: March 04, 2025
Neo - Adjuvant Chemo / Immunotherapy for the Treatment of Resectable Stage IIIA Non Small Cell Lung Cancer (NSCLC): A Phase II Multicenter Exploratory Study
Neo - Adjuvant Chemo / Immunotherapy for the Treatment of Resectable Stage IIIA Non Small Cell Lung Cancer (NSCLC): A Phase II Multicenter Exploratory Study
Enrollment Status: Completed
Publish Date: December 04, 2024
Intervention Type: Drug
Study Drugs: Nivolumab, Paclitaxel, Carboplatin
Study Phase: Phase 2
A Phase II Exploratory Study of Durvalumab (MEDI4736) in HIV-1 Patients With Advanced Solid Tumors.
A Phase II Exploratory Study of Durvalumab (MEDI4736) in HIV-1 Patients With Advanced Solid Tumors.
Enrollment Status: Completed
Publish Date: June 24, 2024
Intervention Type: Drug
Study Drug: Durvalumab
Study Phase: Phase 2
A Phase 3, Randomized, Open-label, Multicenter Study of the Efficacy and Safety of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC) Harboring a HER2 Exon 20 Mutation Who Progressed on or After Treatment With Platinum Based Chemotherapy
A Phase 3, Randomized, Open-label, Multicenter Study of the Efficacy and Safety of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC) Harboring a HER2 Exon 20 Mutation Who Progressed on or After Treatment With Platinum Based Chemotherapy
Enrollment Status: Unknown
Publish Date: March 08, 2023
Intervention Type: Drug
Study Drugs: Pyrotinib, Docetaxel
Study Phase: Phase 3
Observational Retrospective Register of Spanish Lung and Melanoma Cancer Patients With COVID19 Disease
Observational Retrospective Register of Spanish Lung and Melanoma Cancer Patients With COVID19 Disease
Enrollment Status: Completed
Publish Date: June 27, 2022
Spanish Real World Data on Unresectable Stage III NSCLC Patients Treated With Durvalumab After Chemoradiotherapy.
Spanish Real World Data on Unresectable Stage III NSCLC Patients Treated With Durvalumab After Chemoradiotherapy.
Enrollment Status: Completed
Publish Date: June 07, 2022
Intervention Type: Drug
A Retrospective, Multicenter and Observational Study of Osimertinib Monotherapy Treatment in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer EGFR-T790M Mutation-positive Who Have Received the Treatment Within the Special Use Medication Program in Spain
A Retrospective, Multicenter and Observational Study of Osimertinib Monotherapy Treatment in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer EGFR-T790M Mutation-positive Who Have Received the Treatment Within the Special Use Medication Program in Spain
Enrollment Status: Completed
Publish Date: June 03, 2022
Intervention Type: Drug
Study of Acquired Immunity in Patients With Lung Cancer and COVID-19 Infection
Study of Acquired Immunity in Patients With Lung Cancer and COVID-19 Infection
Enrollment Status: Completed
Publish Date: June 03, 2022
Intervention Type: Diagnostic test
T790M Mutation Testing in Blood by Different Methodologies_RING Project
T790M Mutation Testing in Blood by Different Methodologies_RING Project
Enrollment Status: Completed
Publish Date: April 08, 2020
Intervention Type: Drug
View 14 Less Clinical Trials

48 Total Publications

Biomarker landscape in advanced NSCLC: insights from a national prospective registry.
Biomarker landscape in advanced NSCLC: insights from a national prospective registry.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: April 23, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Bernabe's expertise for a condition
ConditionClose
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile